Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04552236 | Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment | unknown | — | 100 | Assiut UniversityOTHER | 0 | Sep 17, 2020 | clinicaltrials |
| NCT04538313 | A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs | unknown | Phase 1 / Phase 2 | 40 | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.NETWORK | 1 | Sep 4, 2020 |
| clinicaltrials |
| NCT03754192 | Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma(PERCAHEC) | unknown | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT04527679 | Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04523402 | Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis | unknown | Phase 2 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04523467 | Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma | unknown | N/A | 320 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 27 | Beijing Tsinghua Chang Gung HospitalOTHER | 0 | Aug 21, 2020 | clinicaltrials |
| NCT04521491 | A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells | unknown | N/A | 184 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04518774 | Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial | unknown | Early Phase 1 | 8 | Beijing 302 HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04513119 | The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis. | unknown | — | 100 | Southwest Hospital, ChinaOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04506281 | PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | unknown | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04297202 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma(HCC-009) | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT02162914 | Regorafenib Versus Placebo to Treat Cholangiocarcinoma(REACHIN) | unknown | Phase 2 | 66 | Erasme University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT04494022 | Role of CEUS as a Secondary Diagnostic Modality | unknown | N/A | 120 | Seoul National University HospitalOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03943043 | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 85 | Istituto Clinico HumanitasOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03642561 | Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE | unknown | Phase 2 / Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02169765 | HR Versus RFA for Early Stage HCC(ARTC-HCC) | unknown | Phase 3 | 120 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03734926 | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 90 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03974074 | Albumin for Hepatocellular Carcinoma | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04104074 | Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis | unknown | Phase 1 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04460157 | Prediction of Liver-related Outcomes After HCV Cure | unknown | — | 1,035 | Hospital Universitario de ValmeOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04411706 | A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 46 | Xin-Hua XuOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT04333927 | Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer(ACCORD) | unknown | Phase 2 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT04386772 | Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma | unknown | N/A | 56 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04434989 | SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma(SAIL) | unknown | N/A | 170 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04435977 | Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma(Immunocabo) | unknown | Phase 2 | 46 | Istituto Clinico HumanitasOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT02971345 | Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus | unknown | Phase 3 | 253 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04413734 | Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 120 | Zhejiang UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04414956 | Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma | unknown | N/A | 1,418 | Korea UniversityOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04415190 | the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients | unknown | — | 150 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT03588442 | Prospective Surveillance for Very Early Hepatocellular Carcinoma(PRECAR) | unknown | — | 10,000 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | May 22, 2020 | clinicaltrials |
| NCT03780049 | HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B | unknown | Phase 3 | 304 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT04392700 | A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection | unknown | Phase 3 | 706 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT04368182 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 3 | Zhejiang UniversityOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT03116984 | A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC(TACE-EBRT) | unknown | Phase 3 | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03971747 | AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 9 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Apr 7, 2020 | clinicaltrials |
| NCT04080154 | Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma(ALTER-H-002) | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT04143191 | Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC(SOURCE) | unknown | Phase 3 | 158 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04237740 | Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation(RRHCCLT) | unknown | Phase 3 | 40 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT04319484 | Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(LLTHVV) | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT04309747 | A Prospective, Multicenter Clinical Trial of Safety and Effectiveness of Nanosecond Knife Ablation for Liver Cancer | unknown | N/A | 190 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Mar 17, 2020 | clinicaltrials |
| NCT02533700 | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | unknown | Phase 2 | 106 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04163627 | Changing Trends in HCC Procedures | unknown | — | 1,000 | University Hospital, MontpellierOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04189809 | Discrepancies in Management of Hepatocellualr Carcinoma Between Practice and Recommendations | unknown | — | 1,000 | University Hospital, MontpellierOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04299919 | The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment | unknown | — | 1,200 | The First Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT04300959 | Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT04273100 | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC(PLTHCC) | unknown | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Sep 17, 2020source: clinicaltrials